%0 Journal Article
%T Male breast cancer: a multicenter study to provide a guide for proper management.
%A Lissidini G
%A Nicosia L
%A Sargenti M
%A Cucchi MC
%A Fabi A
%A Falco G
%A Gardani M
%A Grilz G
%A Maugeri I
%A Murgo R
%A Neri A
%A Pellini F
%A Sensi C
%A Scomersi S
%A Taffurelli M
%A Bagnardi V
%A Oriecuia C
%A Pagan E
%A Sangalli C
%A Dessena M
%A Veronesi P
%A Galimberti V
%J Breast Cancer Res Treat
%V 0
%N 0
%D 2024 Jun 19
%M 38896332
%F 4.624
%R 10.1007/s10549-024-07380-0
%X <B>BACKGROUND: </B>To offer an extensive retrospective experience on the management of male breast cancer.<BR><B>METHODS: </B>A multicenter retrospective observational cohort study was conducted, including male patients diagnosed with breast cancer (invasive or in situ) in 12 Italian breast units from January 1975 to December 2019. Patients aged 18 years or older were assessed for eligibility. Exclusion criteria were metastatic cancer at diagnosis, previous cancer(s), received neoadjuvant treatment, incomplete data on (neo) adjuvant treatment(s), and/or follow-up data. Data on radiological examinations, demographic characteristics, risk factors, histological features, receptor status, treatments, and follow-up were collected.<BR><B>RESULTS: </B>In a series of 671 male patients with breast cancer assessed for eligibility, 403 (28 in situ and 375 invasive neoplasms) were included in the study. All included patients underwent surgery. The median age at surgery was 63.8 years (IQR 56.1-72.1). In 68% of cases, patients underwent echography, and in 55.1%, a mammography. Most patients were ER and PR positive (63.8%), HER2 negative (80.4%), with high (≥ 20%) Ki67 values (61.3%), and luminal B subtype (51.1%). The 10-year overall survival was 73.6% (95% CI 67.0-79.1) for invasive breast cancer and 90% (95% CI 65.6-97.4) for in situ breast cancer. In patients with invasive breast cancer, at univariable analysis, having a G3 tumor (vs. G1), pT2/3/4 (vs. pT1), pN2/3 (vs. pN0), luminal B subtype with Ki67 ≥ 20% (vs. Luminal A), were significantly associated with a higher risk of death. In multivariable analyses, pT2/3/4 (vs. pT1) remained significantly associated with a higher risk of death (HR 3.14, 95% CI 1.83-5.39), and having a HER2 positive or a triple-negative subtype (vs. Luminal A) was also significantly associated with a higher risk of mortality (HR 4.76, 95% CI 1.26-18.1).<BR><B>CONCLUSIONS: </B>Male breast cancer is a rare disease, the better understanding of which is necessary for a more effective diagnostic and therapeutic approach.